Governor Josh Stein announced that Novartis will expand its pharmaceutical manufacturing operations in North Carolina. The company says it expects to create 700 new jobs by the end of 2030 in Durham and Wake counties, while investing $771 million in the City of Durham and Town of Morrisville.
The expansion, which combines new construction with the renovation of existing facilities across three sites, will nearly double Novartis’ operational footprint to more than 700,000 square feet, significantly increasing the company’s manufacturing capacity.
Novartis manufactures gene therapies in Durham and this expansion will support a broader portfolio of pharmaceutical products, including advanced biologics manufacturing, filling and packaging capabilities, as well as small molecule medicines.
Novartis’ expansion in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) awarded to Novartis Gene Therapies, Inc., which was approved by the state’s Economic Investment Committee earlier today. Over the course of the 12-year term of this grant, the project is estimated to grow the state’s economy by $3.1 billion.
